UBS Group
DNA icon

UBS Group’s Ginkgo Bioworks DNA Stock Holding History

UBS Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.57M Buy
582,799
+93,381
+19% +$777K ﹤0.01% 4415
2025
Q4 		$4.07M Buy
489,418
+226,861
+86% +$2.44M ﹤0.01% 4236
2025
Q3 		$3.83M Sell
262,557
-49,399
-16% -$591K ﹤0.01% 4309
2025
Q2 		$3.51M Buy
311,956
+29,340
+10% +$227K ﹤0.01% 4236
2025
Q1 		$1.61M Sell
282,616
-103,731
-27% -$1.06M ﹤0.01% 4882
2024
Q4 		$3.79M Buy
386,347
+369,607
+2,208% +$3.17M ﹤0.01% 4120
2024
Q3 		$136K Buy
16,740
+4,925
+42% +$49.3K ﹤0.01% 6137
2024
Q2 		$158K Sell
11,815
-3,450
-23% -$103K ﹤0.01% 5829
2024
Q1 		$708K Buy
15,265
+9,725
+176% +$503K ﹤0.01% 4904
2023
Q4 		$375K Sell
5,540
-4,586
-45% -$281K ﹤0.01% 5328
2023
Q3 		$733K Buy
10,126
+3,679
+57% +$294K ﹤0.01% 4359
2023
Q2 		$480K Buy
6,447
+1,516
+31% +$89.7K ﹤0.01% 4857
2023
Q1 		$262K Sell
4,931
-3,364
-41% -$213K ﹤0.01% 5186
2022
Q4 		$561K Buy
8,295
+635
+8% +$58.4K ﹤0.01% 4608
2022
Q3 		$956K Buy
7,660
+6,044
+374% +$720K ﹤0.01% 3781
2022
Q2 		$154K Sell
1,616
-932
-37% -$114K ﹤0.01% 5110
2022
Q1 		$411K Buy
2,548
+2,484
+3,881% +$483K ﹤0.01% 4829
2021
Q4 		$21K Buy
64
+18
+39% +$8.55K ﹤0.01% 7775
2021
Q3 		$21K Buy
+46
New +$22.4K ﹤0.01% 7107

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's DNA Position: Q1 2026 in Review

UBS Group increased its Ginkgo Bioworks (DNA) stake by 19% in Q1 2026, buying an estimated $777K and bringing the position to 582,799 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #4415.

UBS Group first reported a position in DNA in Q3 2021 and has held it in 19 quarters since. The position peaked at $4.07M in Q4 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • UBS Group held 582,799 shares of Ginkgo Bioworks worth $3.57M as of Q1 2026.
  • UBS Group bought 93,381 Ginkgo Bioworks shares in Q1 2026, an estimated $777K.
  • Ginkgo Bioworks made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4415 holding.
  • UBS Group first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 19 quarters since.
  • UBS Group's Ginkgo Bioworks position peaked at $4.07M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.